Introduction {#Sec1}
============

Prostate cancer is one of the most common forms of cancer in men and the second cause of death \[[@CR1]\]. Androgens and androgen receptor signaling play an important role in the normal growth and function of the prostate, but also in the development and maintenance of prostate cancer. The beneficial effect of castration in the treatment of prostate cancer has already been discovered in 1941, by Huggins \[[@CR2]\]. LHRH agonists are the most chosen form of chemical castration \[[@CR3]\]. LHRH agonists bring the serum testosterone to a level similar to castration by interfering in the pulsatile release of LHRH in the hypothalamus, thereby down-regulating the release of luteinizing hormone in the anterior pituitary gland. Androgen deprivation therapy (ADT) achieves a remission in 80--90% in men with advanced prostate cancer and an average progression-free interval of 12--33 months \[[@CR4]\].

Despite the fact that this form of therapy is very successful, it also known for its side effects and the impact of these side effects on the quality of life in addition to the psychological and physical effects influencing the quality of life in the long term. The most common life quality diminishing side effects are reduced libido, depression, fatigue, gynecomastia, hot flushes, obesity, hypertension, insulin resistance, and osteoporosis \[[@CR5]\].

Non-pharmaceutical lifestyle interventions aimed to reduce side effects while aiming to leave control in the hands of the patient are very important. They may prevent medicalization and are thought to increase quality of life.

Previous reviews have shown that physical activity may alleviate side effects of ADT \[[@CR6], [@CR7]\]. These reviews mainly focused on the effects of different types of exercise, but did not include all types of lifestyle interventions. The aim of this research is to provide a comprehensive overview of recent physical and psychological lifestyle interventions to reduce different side effects of ADT and to investigate the impact of these interventions on quality of life.

Methods {#Sec2}
=======

Data acquisition and search strategy {#Sec3}
------------------------------------

A literature search was conducted using the electronic databases Medline and PubMed. The literature search included relevant publications until January 25, 2019. Predefined search terms were used to identify articles concerning interventions to reduce side effects of ADT used as a therapy for prostate cancer.

Eligibility criteria {#Sec4}
--------------------

To be eligible, the study population had to consist of patients diagnosed with local or advanced PCa in whom ADT was started. Studies had to be randomized controlled trials (RCTs) that focused on side effects of ADT and lifestyle interventions to reduce those side effects. For this review, we selected studies concerning the following psychological effects: quality of life (health-related quality of life and disease-specific quality of life), fatigue, reduced libido, and depression. We selected studies investigating the following physical side effects: gynecomastia, hot flushes, osteoporosis, obesity, or a decreased cardiovascular health. Lifestyle interventions were defined as interventions that included any dietary or behavioral components. Studies reporting on medical therapies to diminish side effects were excluded, as were studies in which the participants stopped their ADT and studies not related to humans.

Screening of abstracts and full-text articles {#Sec5}
---------------------------------------------

A search was performed for abstracts that may be used for inclusion. Abstract screening was done according to predefined inclusion and exclusion criteria. Full-text original articles were retrieved from the selected abstracts; only articles published in English or Dutch that were available for review were selected. Abstracts and original articles were independently assessed by two reviewers for eligibility (MG and NP). Disagreements were solved by consensus procedure in which an independent third author (HBLG) was conducted.

Subsequently, reference lists of all full-text articles were screened to identify additional relevant articles not found in the PubMed and Medline databases. The final number of included and excluded studies is illustrated in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow chart of the search and selection process

Study quality assessment tool {#Sec6}
-----------------------------

The Cochrane Collaboration's tool was used to assess the risk of bias in the randomized controlled trial \[[@CR8]\]. Two reviewers (MG and NP) assessed the overall quality. If no agreement could be reached, an independent person was involved (HPB).

Data synthesis {#Sec7}
--------------

The following data were independently extracted from full-text articles by two reviewers: study year, study design, study population, mean age, type of interventions, duration and frequency of interventions, relevant study outcomes, and methods to assess these outcomes.

Results {#Sec8}
=======

Search results and analysis {#Sec9}
---------------------------

Our literature search identified 1961 of which 29 articles were included in this analysis. The studies were all RCTs investigating the effect of life style interventions to mitigate ADT-induced side effects. Twenty studies investigated exercise modalities, two studies investigated dietary advice, and four studies combined these methods. Three studies investigated behavioral components, existing of cognitive behavioral therapy, educational support programs, or self-education. Study characteristics are depicted in Table [1](#Tab1){ref-type="table"}.Table 1Study characteristics of the included studiesStudy yearPatients (*n*)Age (mean)Inclusion criteriaInterventionsDuration intervention (weeks) + frequency (*x*/week)Relevant outcomesMethods to assess relevant outcomesSegal \[[@CR9]\]Int: 82Con: 73Total: 155Int: 68.2Con: 67.7Local and advancedPCa receiving ADT ≥ 3 monthsSupervised resistance exerciseDuration: 12Frequency: 3FatigueOverweightQuality of lifeFACT-FBMI, waist circumference, skinfolds thicknessFACT-PTaylor \[[@CR10]\]Life: 46Educ: 51Con: 37Total: 134Int + Con: 69.2PCa treated with ADTLifestyle activity programEducational support programDuration 24 Frequency: week 1--16: 14 week: 2OverweightDepressionQuality of lifeBMI: Waist and hip circumferences, waist-hip ratioCES-DSF-36, STAISharma \[[@CR11]\]Soy: 20Con: 19Total 39Soy: 69.2Con: 69.0PCa treated with ADTSoy protein: 20 gDuration: 12Frequency: 7FatigueLibido and sexual functionHot flushesQuality of lifeSF-36IIEF, WSFSBlatt-Kupperman scale SF-36Culos-Reed \[[@CR12]\]Int: 53Con: 47Total: 100Int: 67.2Con: 68PCa localized or metastatic and expect to receive ADT for ≥ 6 monthsSupervised and unsupervised aerobic + resistant exerciseDuration: 16Frequency: 3--5FatigueOverweightCardiovascular LibidoDepressionQuality of lifeFSSBMI, waist-to-hip ratioRREPICCES-DEORTC-QLQ-C30, EPICGalvao \[[@CR13]\]Int: 29Con: 28Total: 57Int: 69.5Con: 70.1Locally or advanced PCa (without bone metastasis) with prior exposure ADT \> 2 monthsSupervised aerobic + resistance exerciseDuration: 12Frequency: 2FatigueOverweightCardiovascularInsulin resistanceQuality of lifeQLQ-C30, SF-36Dual X-ray absorptiometry: total lean body mass, regional lean mass: upper limb, lower limb, appendicular skeletal muscle total fat mass, trunk fat mass, and percentage body fat, Blood samples: total cholesterol, LDL, HDL, triglycerides, CRP 400 m walkBlood samples: Insulin + glucoseEORTC-QLQ-C30; SF-36Bourke \[[@CR14]\]Int: 25Con: 25Total: 50Int: 71.3Con: 72.2Non localized PCa who receiving ADT ≥ 6 monthsSupervised + unsupervised aerobic + resistance exerciseDuration: 12 Frequency: Resistance + aerobic: week 1--6: 1; 7--12:2xEating seminars: 1xFatigueOverweightInsulinresistance Quality of lifeFACT-FBMI; weight; waist-to-hip ratio Blood biomarkers: insulin; IGF-1FACT-P; FACT-GCormie \[[@CR15]\]Int: 29Con: 28Total: 57Int: 69.5Con: 70.1Locally PCa, on ADT ≥ 2 months and remained hypogonadal for ≥ 6 monthsSupervised aerobic + resistance exerciseDuration: 12Frequency: 2Libido and sexualfunctionQuality of lifeQLQ-PR25SF-36Hvid \[[@CR16]\]Int: 10Con: 9Total: 19Int: 67.8Con: 68.5PCa with ADT \> 3 monthsControl group: healthy malesSupervised enduranceExerciseDuration: 12Frequency: 3OverweightCardiovascularInsulin resistanceDual x-ray absorptiometry: body lean mass, fat mass, trunk fat mass MR: femoral to liver distance, visceral fat mass, skin fat mass, intermuscular adipose tissue Tissue samples: m. vastus lateralisBlood biomarkers: total cholesterol, LDL, HDL, triglyceridesVO2 MaxOGTT Euglycemic--hyperinsulinemic clampBlood samples: glucose, insulinGlucose kinetics calculationsSanta Mina \[[@CR17]\]Aer: 32Res: 34Total: 66Aer: 72.1Res: 70.6PCa currentlyreceiving ADT ≥ 12 monthsSupervised and unsupervised aerobic or resistance exerciseDuration: 26FrequencyTotal: 3--5Supervised: 1 × 2 weekFatigueOverweightGynecomastiaCardiovascularQuality of lifeFACT-FBMI, Body fat, waist circumference, body fat: Skinfolds:chest, abdomen + thigh Chest skinfold thickness VO2 maxFACT-P; PORPUSVitolins \[[@CR18]\]Soy: 30Ven: 30 V + S: 30Con: 30Total:120Soy: 71Ven: 67V + S: 69Con: 67Locally advanced or metastatic PCa on ADT and having hot flushesSoy protein: 20 gVenlafaxineDuration: 12Frequency: dailyHot flashesQuality of lifeHFSSSFACT-P; FACT-GWalker \[[@CR19]\]Int: 20Con: 20Total: 40NRPCa on ADTEducation booklet on side effectsEducational review surveyNALibidoPAIR inventory: DAS scaleSexual activityBourke \[[@CR20]\]Int: 50Con: 50Total: 100Int: 71Con: 71Locally advanced or metastatic PCa, previously on ADT ≥ 6 months and planned long term on ADTAerobic + resistanceExercise + dietary adviceDuration: 12FrequencyResistance: week 1--6: 2x; 7--12: 1xAerobic: week 1-6: 1; 7--12: 2xDietary: 1 × 2 weeksFatigueOverweightCardiovascularQuality of lifeFACT-FBMI; weightSystolic blood pressure, aerobic exercise toleranceFACT-PUth \[[@CR21]\]Int: 29Con: 28Total: 57Int: 67.1Con: 66.5Advanced or locally advanced PCa with ADT or surgical castration ≥ 6 monthsSupervised football trainingDuration: 12Frequency: week 1--8: 2week 9--12: 3OverweightCardiovascularDual X-ray absorptiometry: lean body mass, android, gynoid total body fat mass: BMI; waist circumference; hip circumferenceVO2 max: 4-min walking test; incremental test to exhaustion Pulmonary gas exchange measurementsHeart rate monitorsWinters- stone \[[@CR22], [@CR23]\]Int: 29Con: 22Total: 51Int: 69.9Con: 70.5Localized or metastatic PCa currently receiving ADTInt: Supervised + unsupervised resistance exerciseCont: StretchingDuration: 52Frequency: 3FatigueOverweightInsulin resistanceQuality of lifeSCFS BMIDual X-ray absorptiometry: Fat mass; Bone-free lean mass; trunkfat massBlood biomarkers: insulin; IGF-1LLFDICormie \[[@CR24]\]Int: 32Con: 31Total: 63Int: 69.6Con: 67.1PCa within first 10 days on ADT and anticipated to remain on ADT ≥ 3 monthsSupervised aerobic + resistance exerciseDuration: 12Frequency: 2FatigueOverweightCardiovascularOsteoporosisLibidoInsulin resistanceDepressionQuality of lifeFACIT-fatigueDual X-ray absorptiometry: body lean mass, fat mass, appendicular lean mass, trunk fat mass, visceral fat massBlood biomarkers: CRP VO~2~ max: 400-m walk test RR: brachialDual X-ray absorptiometry: BMD: hip, lumbar spine, whole body Blood biomarkers: alkaline phosphatase, P1NP, N-telopeptide, N-telopeptide/creatinin*e* ratio, vitamin DQLQ-PR25Blood biomarkers: Insulin, glucoseBSI-18QLQ-PR25; SF-36Nilsen \[[@CR25]\]Int: 28Con: 30Total: 58Int: 66Con: 66Locally advanced PCa receiving RT after neo-adjuvant ADT for 6 months and adjuvant ADT 9--36 monthsSupervised resistance exerciseDuration: 16Frequency: 3OverweightFatigueOsteoporosisCardiovascularQuality of lifeDual x-ray absorptiometry: lean body mass, Regional LBM: (trunk, lower extremities, upper extremities, appendicular skeletal mass), fat mass, fat percentage, body mass, BMIEORTC- QLQ-C30Dual X-ray absorptiometry: BMD: total, total lumbar spine, hip, trochanter and femoral neck Shuttle walk testEORTC-QLQ-C30O'neill \[[@CR26]\]Int: 47Con: 47Total: 94Int: 69.7Con: 69.9PCa treated ADT for ≥ 6 months and planned to continue for ≥ 6 months or commencing to start ≥ 6 monthsAerobic exercise + dietary adviceDuration: 26Frequency: Walking: 5OverweightFatigueCardiovascularQuality of lifeWeight, BMI, fat mass, lean muscle mass, waist-to-hip ratio, mid-upper arm muscle areaFat mass: Skinfold thickness FSS400-m walk test FACT-P; PSSStefanopoul ou \[[@CR27]\]Int: 33Con: 35Tot: 68Int: 68.0Con: 68.7Localized or metastaticPCa undergoing ADTCBT bookletDuration: 4HotFlushesDepressionQuality of lifeHFNSHADSEORTC-QLQ-C30; EORTC- QLQ-PR25Gilbert \[[@CR28]\]Int: 25Con: 25Total: 50Int: 70.1Con: 70.4PCa receiving ADT ≥6 months + radiotherapySupervised + unsupervised aerobic, balance, resistance exercise + Dietary advice: healthy-eating seminarsDuration 12Frequency: Training: 3 Diet: 1 × 2 weekOverweightCardiovascularBMI, weightBlood biomarkers: total cholesterol, LDL, HDL, triglyceridesRR: Brachial artery FMD, GTN-arterial dilatationVO2 max: Exercise tolerance: walking testNilsen \[[@CR29]\]Int: 16Con: 15Total: 31Int: 66Con: 65Locally advanced PCa receiving RT after neo-adjuvant ADT for 6 months and adjuvant ADT 9-36 monthsSupervised resistance exerciseDuration: 16Frequency: 3OverweightMuscles biopsies m. Vastus lateralis: protein concentrations, HSP70, Alpha B-crystalline, HSP27, HSP27, HSP60, C OXIV, Citrate synthase UbiquitinNilsen \[[@CR30]\]Int: 12Con: 11Total: 23Int: 67Con: 64Locally advanced PCa receiving RT after neo-adjuvant ADT for 6 months and adjuvant ADT 9--36 monthsSupervised resistance exerciseDuration: 16Frequency: 3OverweightMuscle biopsies m. Vastus lateralis: histology, muscle fiber CSA, myonuclei, satellite cells, protein concentrationsSajid \[[@CR31]\]EXCAP: 6Wii-fit: 8Con: 5Total: 19EXCAP: 75.7Wii-fit77.5Con: 71.8PCa with ADT, ADT combined with RTEXCAP: Unsupervised aerobic exercise + resistance exerciseWii-fit: Multi- component exercise on WIIDuration: 6Frequency: 5Fatigue OverweightSPPBDual X-ray absorptiometry: body fat mass, body lean mass, skeletal muscle massUth \[[@CR32]\]Int: 29Con: 28Total: 57Int: 67.1Con: 66.5Locally advanced or metastatic PCa undergoing ADT for ≥ 6 monthsSupervised football exerciseDuration: 32 Frequency: week 1--: 2week 9--12: 3week 12--32: 2OverweightOsteoporosisDual X-ray absorptiometry: body lean mass, fat mass, percentage fat mass, Dual x-ray absorptiometry: BMD: total hip, femoral, lumbar spine, Blood samples: P1NP, osteocalcin, CTXUth \[[@CR33]\]Int: 29Con: 28Total: 57Int: 67.1Con: 66.5Locally advanced or metastatic Pca undergoing ADT for ≥ 6 monthsSupervised footballexerciseDuration: 12Frequency:wk 1-8: 2wk 9-12: 3OsteoporosisDual X-ray absorptiometryBMC: total body, legsBMD: total body, legsBlood biomarkers: CTX, P1NP, osteocalcinKim \[[@CR34]\]Int: 26Con: 25Total: 51Int: 70.5Con: 71.0PCa Stage I to IIIreceiving ADTUnsupervised strength training + resistance exerciseDuration: 26Frequency: 3-5OsteoporosisQuality of lifeDual x-ray absorptiometry: total BMD, regional BMD: Total hip, femur neck, lumbar spine, Blood samples: bs-ALP, NtxFACT-PTaaffe \[[@CR35]\]ILRT: 58ART: 54Con: 51 Total:163ILRT:68. 9ART: 69Con: 68.4PCa withADT exposure ≥ 2 months, anticipated toreceive ADT following12 monthsSupervised impact + resistance exercise (ILRT)Supervised + unsupervised aerobic + resistance exercise (ART)Duration: 52 Frequency: ILRT + AER: 2Fatigue CardiovascularEORTC-QLQ-C30; SF-36400 m walkWall et al. \[[@CR36]\]Int: 50Con: 47Total: 97Int: 69.1Con: 69.1Localized PCa on ADT for ≥ 2 monthsSupervised and unsupervised aerobic + resistance exerciseDuration: 26Frequency: 2OverweightCardiovascularInsulin resistanceDual X-ray absorptiometry: lean body mass, fat mass, trunk fat mass, percentage body fat, appendicular fat mass, weightBlood biomarkers: CRPRespiratory gas analysis: fat oxidation, carbohydrate oxidationBlood samples: LDL; HDL; cholesterol, triglycerides VO2Max; RR: brachial Applanation tonometry: arterial stiffness, aortal blood pressure Carotid-to-radial pulse-wave Blood biomarkers: Insulin: Hba1c, glucoseDawson \[[@CR37]\]Int: 13Con: 19Total: 32Pro: 68.6Con: 66.3PCa with ADTSupervised resistance trainingDuration: 12Frequency: 3Fatigue OverweightCardiovascularInsulin resistanceDepression Quality of lifeBFIDual X-ray: appendicular skeletal mass, lean body mass, fat mass, percentage body fat, waist circumferenceSystolic blood pressure, diastolic blood pressureBlood biomarkers: Glucose CES-DFACT-G; FACT-P*RCTs* randomized controlled trials; *Int* intervention group, *Con* control group, *PCa* prostate cancer, *ADT* androgen deprivation therapy, *RT* radiotherapy, *Ven/V* venlafaxine, *Soy/S* soy protein, physical examinations, *BMI* body mass index, *LBM* lean body mass, *BMD* bone mineral density, *BMC* bone mineral content, *PPB* positive pressure, breathing, *RR* blood pressure, *OGTT* oral glucose tolerance test, *VO2 max* maximal oxygen consumption, *FMD* flow-mediated dilatation, *GTN-arterial dilatation* glyceryl trinitrate-arterial dilatation*Blood biomarkers* IGF-1: Insulin Growth Factor-1, IGFBP: Insulin-Like Growth Factor-Binding Peptide, IGFBP-1: Insulin-Like Growth Factor-Binding Peptide-1, IGFBP-3: Insulin-Like Growth Factor-Binding Peptide-3, Hba1c: Glycosylated Hemoglobin type A1c, LDL: Low Density Lipoprotein, HDL: High Density Lipoprotein, CRP: C-Reactive Protein, CTX: Cyclophosphamide, P1NP: Procollagen Type 1, bs-ALP: bone-specific Alkaline Phosphatase, NTX: N-Telopeptide of type I collagen*Questionnaires* CES-D: Center for Epidemiologic Studies Depression scale, HADS: Hospital Anxiety and Depression Scale, DAS scale: Depression, Anxiety and Stress scale, BFI: Big Five Inventory, BSI-18: Brief Symptom Inventory 18, FSS: Fatigue Severity Scale, FACT-P: Functional Assessment of Cancer Therapy-Prostate; FACT-G: Functional Assessment of Cancer Therapy General; FACT-F: Functional Assessment of Cancer Therapy Fatigue POMS: Profile Of Mood Status; EIFI-exhaustion: The Exercise-Induced Feeling Inventory EORTC-QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, EORTC-QLQ-PR25: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Prostate-Specific 25-item, SF-36: short-form health survey (36), EPIC: Expanded Prostate Cancer Index, HFSS: Hot Flashes Severity Score, HFNS: Hot Flushes and Night Sweats, HFSSS: Hot Flushes Severity Symptom Score, PAIR inventory: Personal Assessment of Intimacy in Relationships, SPPB: Short Physical Performance Battery, IIEF: International Index of Erectile Function, WSFS: Watts Sexual Functioning Scale; PORPUS: Patient-Oriented Prostate Utility Scale, PSS: Perceived Stress Scale, LLFDI: Late Life Function and Disability Instrument, STAI: State-Trait Anxiety Inventory

Table [2](#Tab2){ref-type="table"} shows an overview of RCTs testing mitigation strategies for ADT-induced side effects, categorized per side effect. Table [3](#Tab3){ref-type="table"} summarizes the quality scores of the RCTs. The quality differed between the studies. The most common source of methodological bias was a lack of proper blinding procedures. Almost one-third of the studies presented incomplete outcome data.Table 2Overview of RCTs testing mitigation strategies for ADT categorized per side effectSide effectInterventionStudyOutcomesMethods to measure outcomeQuality of lifeAerobic trainingSanta Mina et al. \[[@CR17]\]No differencePRO (FACT-P; PORPUS)Aerobic training + dietary adviceO'neill et al. \[[@CR26]\]Improvement in the individual functional well-being subscale (*P* = 0.04) measured with FACT-P at 26 weeksPRO (FACT-P; PSS)Aerobic + Resistance trainingCulos-Reed et al. \[[@CR12]\]No differencePRO (EORTC-QLQ-C30, EPIC)Galvao et al. \[[@CR13]\]Significant improvement for general health (*P* = 0.022), vitality (*P* = 0.19) and physical health score (*P* = 0.02) measured with SF-36 Significant improvement in role (*P* \< 0.001), cognitive (*P* = 0.007), nausea (*P* = 0.025), dyspnea (*P* = 0.17) measured with QLQ-C30 after 12 weeksPRO (QLQ-C30; SF-36)Bourke et al. \[[@CR14]\]No differencePRO (FACT-P; FACT-G)Cormie et al. \[[@CR24]\]Significant improvement in social functioning (*P* = 0.015), mental health domains (*P* = 0.006) and the mental health composite score (*P* = 0.022) after 12 weeks measured with SF-36PRO (QLQ-PR25; SF-36)Aerobic + resistance + dietary adviceCormie et al. \[[@CR15]\]Significant difference in perceived general health (*P* = 0.022), vitality (*P* = 0.019); physical health composite (*P* = 0.02) subscales measured with SF-36 at 12 weeksPRO (SF-36)Bourke et al. \[[@CR20]\]Significant improvement after 12 weeks (*P* = 0.001), no change after 24 weeks measured with FACT-PPRO (FACT-P)Cognitive behavioral therapyStefanopoulou et al. \[[@CR27]\]No differencesPRO (EORTC-QLQ-C30; EORTC-QLQ-PR25)Resistance trainingSegal et al. \[[@CR9]\]Increase in QOL, compared with a decrease for the control group (*P* = 0.001) measured with FACT-P after 12 weeksPRO (FACT-P)Taylor et al. \[[@CR5]\]No differencesPRO (SF-36, STAI)Santa Mina et al. \[[@CR17]\]No differencesPRO (FACT-P; PORPUS)Nilsen et al. \[[@CR25]\]No differencesPRO (EORTC-QLQ-C30)Kim et al. \[[@CR34]\]No differencesPRO (FACT-P)Dawson et al. \[[@CR37]\]Significant improvement in quality of life measured with FACT-G (*P* = 0.048) and FACT-P (*P *= 0.04)PRO (FACT-G; FACT-P)Soy proteinSharma et al. \[[@CR11]\]No differencesPRO (SF-36)Vitolins et al. \[[@CR18]\]Improvements in emotional (*P* = 0.029) and functional subscales (*P* = 0.041) and in FACT-G (*P* = 0.025) and FACT-P total scores. (*P* = 0.048)PRO (FACT-P; FACT-G)DepressionAerobic + resistance trainingCulos-Reed et al. \[[@CR12]\]No differencesPRO (CES-D)Santa Mina et al. \[[@CR17]\]No differencesPRO (FACT-F)Cormie et al. \[[@CR24]\]No differencesPRO (BSI-18)Cognitive behavioral therapyStefanopoulou et al. \[[@CR27]\]No differencesPRO (HADS)Educational support programTaylor et al. \[[@CR10]\]No differencesPRO (CES-D)Lifestyle activity programTaylor et al. \[[@CR10]\]No differencesPRO (CES-D)Resistance trainingDawson et al. \[[@CR37]\]No differencesPRO (CES-D)FatigueAerobic trainingSanta Mina et al. \[[@CR17]\]No differencesPRO (FACT-F)Aerobic training + dietary adviceO'neill et al. \[[@CR26]\]No differencesPRO (FSS)Aerobic + resistance trainingCormie et al. \[[@CR24]\]Significant reduction (*P* = 0.042) measured with FACIT-fatiguePRO (FACIT-fatigue)Culos-Reed et al. \[[@CR12]\]No differencePRO (FSS)Galvao et al. \[[@CR13]\]Significant reduction in fatigue (*P* = 0.021) and increased vitality (*P* = 0.019) measured with SF-36 and QLQ-C30 resp.PRO (QLQ-C30, SF-36)Santa Mina et al. \[[@CR17]\]No differencesPRO (FACT-F)Sajid et al. \[[@CR31]\]EXCAP: Significant reduction (*P* = 0.04) measured with SPPB Wii-fit: no differencesPRO (SPPB)Taaffe et al. \[[@CR35]\]Significant reduction in fatigue (*P* = 0.005) and increased vitality (*P* \< 0.001) measured with EORTC-QLQ-C30 and SF-36 resp.PRO (EORTC-QLQ-C30; SF-36)Aerobic + resistance training + dietary adviceBourke et al. \[[@CR14]\]Significant reduction at 12 weeks (*P *= 0.002) and 6 months (*P* = 0.006) measured with FACT-FPRO (FACT-F)Bourke et al. \[[@CR20]\]Significant reduction at 12 weeks (*P* \< 0.001) and 6 months (*P* = 0.010) measured with FACT-PPRO (FACT-P)Impact + resistance trainingTaaffe et al. \[[@CR35]\]Significant reduction of fatigue (*P* = 0.005) and increased vitality (*P* \< 0.001)PRO (EORTC-QLQ-C30; SF-36)Resistance trainingSegal et al. \[[@CR9]\]Significant reduction (*P* = 0.002)PRO (FACT-F)Sharma et al. \[[@CR11]\]Significant reduction after 12 weeks (*P* = 0.010) and 24 weeks (*P* = 0.002)Per-group analysis: significant reduction after 24 weeks (*P* = 0.04)PRO (SF-36)Santa Mina et al. \[[@CR17]\]No differencesPRO (FACT-F)Nilsen et al. \[[@CR25]\]No differencesPRO (EORTC- QLQ-C30)Dawson et al. \[[@CR37]\]No differencesPRO (BFI)Soy proteinSharma et al. \[[@CR11]\]No differencesPRO (SF-36)Decreased libido + sexual functionAerobic + resistance trainingCulos-Reed et al. \[[@CR12]\]No difference between groups or effect over time in sexual functionPRO (EPIC)Cormie et al. \[[@CR15]\]Significant difference in percentage of major interest in sex (*P* = 0.024) and maintenance in level of sexual activity (*P* = 0.045) No change in any level of sexual interest or sexual functionPRO (QLQ-PR25)Cormie et al. \[[@CR24]\]Significant less decline in sexual function (*P* = 0.028), no difference in sexual activityPer-group-analysis over time: decline in sexual activity (*P* = 0.012), no change in sexual functionPRO (QLQ-PR25)Information bookletWalker et al. \[[@CR19]\]No significant differences. Sexual activity at baseline: 64.3% versus 38.5% (control), after 6 months: 25% versus 0% (control)PRO (PAIR inventory: DAS scale, sexual activity)Soy proteinSharma et al. \[[@CR11]\]No differencesPRO (IIEF, WSFS)OverweightAerobic trainingHvid et al. \[[@CR16]\]Body composition: no differences Per-group analysis: reduction in BMI (*P* \< 0.0001), weight (*P* \< 0.0001), fat mass (*P* \< 0.01), fat percentage (*P* \< 0.05), trunk fat mass (*P* \< 0.01)Blood biomarkers: no differencesPer-group analysis: Increase in HDL over time. No differences in LDL, total cholesterol, triglyceridesBody composition and blood biomarkersSanta Mina et al. \[[@CR17]\]No differencesBody compositionAerobic training + dietary adviceO'neill et al. \[[@CR26]\]Body composition: significant reduction (all *P* = 0.001), waist-to-hip ratio (*P* = 0.009)No difference in lean body mass or mid-upper arm muscle areaBody compositionAerobic + resistance trainingCulos-Reed et al. \[[@CR12]\]Body composition: significant reduction in waist girth (*P* = 0.044) and neck girth (P-0.019), no difference in BMIPer-group analysis: no difference in BMIBody compositionGalvao et al. \[[@CR13]\]Body composition: significant increase in total lean mass (*P* = 0.047), upper limb (*P* \< 0.001), lower limb (*P* = 0.019), appendicular skeletal mass (*P* = 0.03). No change in weight total body fat mass trunk fat mass or percentage body fatBlood biomarkers: Significant decrease in CRP (*P* = 0.008). No change in other markersBody composition and blood biomarkersCormie et al. \[[@CR24]\]Body composition: significant reduction in appendicular lean mass (*P* = 0.019), whole body fat mass (*P* = 0.001), whole body percentage fat (*P* \< 0.001), trunk fat mass (*P* = 0.008). No differences in total body mass, visceral fat mass or body lean massBlood biomarkers: significant reduction in HDL total cholesterol ratio (*P* = 0.028). No differences in other biomarkersBody composition and blood biomarkersSajid et al. \[[@CR31]\]EXCAP: Body composition: no differencesWii-fit: Body composition: decrease in lean mass for the Wii-fit group (*P* = 0.045),Body compositionWall et al. \[[@CR36]\]Body composition: increase in lean body mass (*P* = 0.015), decrease in total fat mass (*P* = 0.020), trunk fat mass (*P* \< 0.001), body fat percentage (*P *= 0.001), no change in weightBlood biomarkers: no differencesBody composition and blood biomarkersAerobic + resistance training + dietary adviceBourke et al. \[[@CR14]\]No differencesBody compositionBourke et al. \[[@CR20]\]No differencesBody compositionGilbert et al. \[[@CR28]\]Body composition: significant increase in skeletal muscle mass (*P* = 0.03), no difference in BMI or body fat massBlood biomarkers: no differencesBody composition and blood biomarkersEducational support programTaylor et al. \[[@CR10]\]No differencesBody compositionFootball trainingUth et al. \[[@CR21]\]Significant increase in lean body mass (*P* = 0.02), no change in body fat percentage, body fat massPer-group analysis: significant increase in lean body mass (*P* = 0.02), no change in body fat percentage or body fat massBody compositionUth et al. \[[@CR32], [@CR33]\]No differencesBody compositionResistance exerciseUth et al. \[[@CR32], [@CR33]\]No differencesBody compositionSegal et al. \[[@CR9]\]No differencesBody compositionSanta Mina et al. \[[@CR17]\]No differencesBody compositionWinters-stone \[[@CR23]\]Significant reduction in total fat mass in covariance analysis (*P* = 0.02), not in ITT analysisNo significant change in body lean mass, percentage body fat, weight or trunk fat massBody compositionNilsen et al. \[[@CR25]\]Significant increase in LBM in lower extremities (*P* = 0.002) and upper extremities (*P* = 0.048), appendicular skeletal muscle mass (*P* = 0.001). No change in total, trunk lean mass, total fat mass, trunk fat mass, percentage fat mass, weight, or BMIBody compositionNilsen et al. \[[@CR29], [@CR30]\]No significant difference in mitochondrial proteins or indicators of muscle cellular stress: HSP70 B-crystallin; ubiquitin; ubiquittinated proteinsPer-group analysis: change over time in HSP70 (*P* = 0.03)Muscles biopsies m. Vastus lateralis: protein concentrations, HSP70, Alpha B-crystalline, HSP27, HSP27, HSP60, COXIV, Citrate synthase UbiquitinNilsen et al. \[[@CR29], [@CR30]\]Significant change in total muscle fiber in favor for intervention group (*P* = 0.04)Significant increase in type II fibers for intervention group (*P* = 0.03); no change myonuclei numberMuscle biopsies m. Vastus lateralis: histology, muscle fiber CSA, myonuclei, satelite cells, protein concentrationsDawson et al. \[[@CR37]\]Significant increase in lean mass, appendicular skelet mass (*P* = 0.02), sacropenic index (*P* = 0.02), fat free mass (*P* = 0.04). Significant decrease in waist circumference (*P *= 0.01), and percentage body fat (*P* = 0.01). No difference in fat mass or total massBlood biomarkers: No differenceBody compositionHot flushesCognitive Behavioral TherapyStefanopoulou et al. \[[@CR27]\]Decreased hot flashes problem rating (*P* = 0.001) and reduced frequency at 6 weeks (*P* = 0.02).No difference at 32 weeksPRO (HFNS)Soy proteinSharma et al. \[[@CR11]\]Difference in favor of the placebo group at 12 weeks (*P* = 0.04). No difference at 6 weeksPer-group analysis: no difference in vasomotor symptomsPRO (Blatt-Kupperman scale)Vitolin et al. \[[@CR18]\]No differencesPer-group analysis: significant decrease of vasomotor symptoms (*P* \< 0.001), hot flushes severity (*P* \< 0.001), hot flushes symptom severity score (*P* \< 0.001)PRO (HFSS, HFSSS)GynaecomastiaAerobic trainingSanta Mina et al. \[[@CR17]\]No differenceBody compositionResistance trainingSanta Mina et al. \[[@CR17]\]No differenceBody compositionCardiovascularAerobic trainingHvid et al. \[[@CR16]\]No significant difference in VO~2~ max (ml(O~2~)/min per kg), VO2max (ml(O~2~)/minPer-group analysis: increase in VO2 max (ml(O~2~)/min per kg) (*P* \< 0.0001), VO~2~ max (ml(O~2~)/min) (P \< 0.001).Physical test (VO~2~max)No differenceSanta Mina et al. \[[@CR17]\]No differencePhysical test (VO~2~max)Aerobic training + dietary adviceO'neill et al. \[[@CR26]\]Significant change (P = 0.001)Physical test (6-m walk test)Aerobic + resistance trainingCulos-Reed et al. \[[@CR12]\]No differencePer-group analysis: significant reduction of systolic blood pressure (P = 0.011) and diastolic blood pressure (P = 0.004)Blood pressureGalvao et al. \[[@CR13]\]No differencePhysical test (400 m walk test)Cormie et al. \[[@CR24]\]Significant increase in VO2 max (*P* = 0.004) and 400 m walk (*P* = 0.009)No change in blood pressurePhyscial test (VO~2~ max: 400-m walk test) Blood pressureTaaffe et al. \[[@CR35]\]No differencesPer-group analysis: cardiovascular fitness improved ART: *P* \< 0.001Physical test (400 m walk)Wall et al. \[[@CR36]\]Significant increase in VO2 Max (L min) and VO2 Max (ml/kg) (*P* = 0.033), fat oxidation (*P *= 0.037)No change in RMR, carbohydrate oxidation, peripheral systolic, diastolic RR or MAP, central diastolic RR or MAP, peripheral augmentation index, central augmentation pressure, central augmentation, index, pulse-wave velocityPhysical test (Respiratory gas analysis, VO2 Max), blood pressure, blood samplesAerobic + resistance training + dietary adviceBourke et al. \[[@CR20]\]Significant improvement in aerobic exercise tolerance at 12 weeks (*P* \< 0.001) and 6 months (*P* \< 0.001)No difference in systolic blood pressurePhyscial test (aerobic exercise tolerance), blood pressureAerobic, balance, resistance exercise + dietary adviceGilbert et al. \[[@CR28]\]Treadmill walk time improved at 12 and 24 weeks (*P* \< 0.001) Difference in FMD at 12 weeks (*P* = 0.04). No difference in GTN dilatation, systolic blood pressure or diastolic bloodpressurePhysical test (VO2 max, exercise tolerance: walking test), blood pressureFootball trainingUth et al. \[[@CR21]\]No significant difference between groupsPer-group -analysis: VO2 max increased in the intervention group (1.0 ml/kg/min) *P* = 0.02Physical test (VO2 max: 4-min walking test; incremental test to exhaustion, pulmonary gas exchange measurements; heart rate monitors)Impact + resistance trainingTaaffe et al. \[[@CR35]\]No differencesPhysical test (400 m walk)Resistance trainingVO2max improvement (*P* = 0.41), also after adjustment for covariates (*P* = 0.38)Santa Mina et al. \[[@CR17]\]Significant improvement compared to control groupPhysical test (VO2 max)Dawson et al. \[[@CR37]\]No differencesBlood pressure**Insulin resistance**Aerobic trainingHvid et al. \[[@CR16]\]No difference in fasting glucose, glucose AUC or insulin AUC compared to control groupPer-group analysis: significant change in fasting glucose (*P* \< 0.05), no change in glucose AUC or insulin AUCPhysical test (VO2 Max OGTT Euglycemic-- hyperinsulinemic clamp), blood biomarkersAerobic + resistance trainingGalvao et al. \[[@CR13]\]No differencesBlood biomarkersCormie et al. \[[@CR24]\]No differencesBlood biomarkersWall et al. \[[@CR36]\]Significant change for glucose (*P* \< 0.001). No change for Hba1c or insulinBlood biomarkersAerobic + resistance training + dietary adviceBourke et al. \[[@CR14]\]No differencesBlood biomarkersResistance trainingWinters-stone \[[@CR23]\]No differencesBlood biomarkersDawson et al. \[[@CR37]\]No differencesBlood biomarkers**Osteoporosis**Aerobic + resistance trainingCormie et al. \[[@CR24]\]No differencesBody composition, blood biomarkersFootball trainingUth et al. \[[@CR32]\]Bone mineral content: significant increment in total body BMC (*P* = 0.013), leg BMC (*P* \< 0.001)Bone mineral density: no differencesBlood biomarkers: significant change P1NP (*P* = 0.008) and osteocalcin (*P* = 0.002), no change in CTXBody composition, blood biomarkersUth et al. \[[@CR32]\]Bone mineral density: significant increment in left total hip (*P* = 0.030), right total hip (*P* = 0.015), left femoral shaft (*P* = 0.015), right femoral shaft (*P* = 0.016). No difference in right femoral neck, left femoral neck, lumbar spine L2--L4Blood biomarkers: no differencesBody composition, blood biomarkersResistance trainingNilsen et al. \[[@CR25]\]No differencesBody compositionKim et al. \[[@CR34]\]No differencesBody compositionTable 3Methodological quality assessment tool for randomized controlled trialsRandom sequence generation (Selection bias)Allocation concealment (Selection bias)Blinding of participants and personnel (performance bias)Blinding of outcome assessment (attrition bias)Incomplete outcome data (attrition bias)Selective reporting (reporting bias)Other biasSegal \[[@CR9]\]2003++−?−++Taylor \[[@CR10]\]2006−−−+++−Sharma \[[@CR11]\]2009++++?+−Culos-Reed \[[@CR12]\]2010++−+?+−Galvao \[[@CR13]\]2010++−−+++Bourke \[[@CR14]\]2011+?−++??Cormie \[[@CR15]\]2013++−?+++Hvid \[[@CR16]\]2013−−−+−+−Santa Mina \[[@CR17]\]2013?+−+++−Vitolins \[[@CR18]\]2013++++−−−Walker \[[@CR19]\]2013??−?++−Bourke \[[@CR20]\]2014++−−+++Uth \[[@CR21]\]2014++−+++−Winters-Stone \[[@CR22], [@CR23]\]2015??−+++−Cormie \[[@CR24]\]2015++−?+++Nilsen \[[@CR25]\]2015+?−++++O'Neill \[[@CR26]\]2015++−−++?Stefanopoulou \[[@CR27]\]2015++−+−+−Gilbert \[[@CR28]\]2016++−++++Nilsen \[[@CR29]\]2016+?−+−?−Nilsen \[[@CR30]\]2016+?−+−?−Sajid \[[@CR31]\]2016++−+−++Uth \[[@CR32]\]2016++−++?−Uth \[[@CR33]\]2016++−+−+−Kim \[[@CR34]\]2017++−−−+−Taaffe \[[@CR35]\]2017++−+−+?Wall Dawson \[[@CR36], [@CR37]\]20172018++++−−+−−++?++Risk of bias summary for each trial included in the systematic review as evaluated by authors+ low risk of bias; ? Some concerns are risk of bias; − high risk of bias

### Psychological side effects {#Sec10}

#### Quality of life {#Sec11}

Health-related quality of life (HRQOL) is perceived physical and mental health over time either by an individual or by a group. The influence of lifestyle interventions on the quality of life for patients on ADT was examined in 16 studies \[[@CR9]--[@CR15], [@CR17], [@CR18], [@CR20], [@CR23]--[@CR27], [@CR34], [@CR36]\].

Ten different questionnaires were used to measure HRQOL. Some of the questionnaires are developed to examine health-related quality of life in general (STAI; SF-36; EORTC-QLQ- C30; QLQ-PR25; PSS; FACT-G; LFDI). Others are used to investigate prostatic disease-specific quality of life or aspects of quality of life (FACT-P; PORPUS; EPIC). Eleven studies investigated the effects of physical exercises, three combined physical exercises with dietary advice, and two investigated the effect of soy consumption. In four studies, a positive effect of exercise only was noted \[[@CR9], [@CR13], [@CR24], [@CR36]\]. Two out of six studies investigating the effect of resistance training found a positive effect on the health-related quality of life and in one of these studies, an improved disease-specific quality of life had been found \[[@CR36]\]. Aerobic and resistance training combined showed a positive effect in two out of four studies \[[@CR13], [@CR24]\]. In these two studies, only specific domains were significantly improved. For details, see Table [2](#Tab2){ref-type="table"}. Variable results were found when combining exercises with dietary advice. All three studies found positive effects on different aspects of quality of life \[[@CR15], [@CR20], [@CR26]\]. Bourke et al. found an improvement in the prostatic disease-specific quality of life after 12 weeks of training, but this was only temporary since the effect disappeared after 24 weeks \[[@CR20]\]. One study investigated the effect of cognitive behavioral therapy on quality of life, but failed to show an improvement. Two studies investigated the effect of soy consumption. Vitolins et al. found an improved HRQOL as well as an improved disease-specific quality of life after consumption of soy protein, while Sharma et al. failed to show any effect \[[@CR11], [@CR18]\].

#### Depression {#Sec12}

In the treatment of PCa, ADT use is associated with depression. Five studies focused on depression \[[@CR10], [@CR12], [@CR24], [@CR27], [@CR36]\]. Aerobic and/or resistance training failed to show a beneficial effect \[[@CR12], [@CR24], [@CR36]\]. Applied cognitive behavioral therapy (CBT) for a period of four weeks did not show a beneficial effect \[[@CR27]\]. A lifestyle activity program or an educational support program did not influence depression scores using CES-D \[[@CR10]\].

#### Fatigue {#Sec13}

Fatigue is a phenomenon, which is difficult to measure or define. Fatigue is experienced by patients receiving ADT and is associated with decreased levels of testosterone and reduction of skeletal muscle mass may contribute to fatigue. Influence of lifestyle interventions was examined in fourteen studies: ten investigated the effects of physical exercises, three combined physical exercises with dietary advice, and one investigated the effect of soy consumption \[[@CR9], [@CR11]--[@CR14], [@CR17], [@CR20], [@CR24]--[@CR26], [@CR31], [@CR35], [@CR36]\]. Soy consumption showed no effect \[[@CR11]\].

Different exercise modalities yield conflicting results in relation to fatigue. Generally speaking, in half of the studies, a reduction in fatigue was noted. Combining exercises with dietary advice showed a beneficial effect in two studies \[[@CR14], [@CR20]\]. Another study failed to show improvement \[[@CR26]\].

#### Decreased libido and sexual function {#Sec14}

Since androgens play an essential role in maintaining sexuality, e.g., libido and erectile function, it is obvious that ADT causes a decrease in sexual activity and may result in a variety of sexual problems. Five studies investigated methods to counteract decreased libido and erectile function \[[@CR11], [@CR12], [@CR15], [@CR19], [@CR24]\]. Aerobic and resistance exercises were examined in three studies in which contradictory findings were reported. In 2013, Cormie et al. found maintenance of major interest in sex as well as sexual activity in the exercise group. No change in sexual function was noted. In 2015, Cormie et al. reported a diminished decline in sexual function in favor of the exercise group. In per-group analysis, a decline in sexual activity was found without change in sexual function \[[@CR24]\]. Culos-Reed et al. found no differences \[[@CR12]\].

Patient information concerning the side effects of ADT followed by an educational partner session failed to show an effect on libido, measured by the PAIR and DAS-scores which, respectively, assess the current level of intimacy in one's relationship and the relationship adjustment. Couples participating in the intervention were more successful at maintaining sexual activity \[[@CR19]\]. Soy protein consumption did not influence libido or sexual function \[[@CR11]\].

### Physical side effects {#Sec15}

#### Gynecomastia {#Sec16}

Gynecomastia may develop in ADT. In one study, gynecomastia was measured by skinfold thickness and was not influenced by aerobic or resistance training \[[@CR17]\].

#### Hot flushes {#Sec17}

Hot flushes are defined as intense heat sensation, flushing, and perspiration involving face and trunk. Anxiety and palpitations may occur. ADT may induce these complaints because the decline in LH and FSH causes the release of hypothalamic catecholamines disrupting the thermoregulation center in the upper hypothalamus. CBT temporarily lowers the occurrence of hot flushes and problem rating in men \[[@CR27]\]. Only at 6 weeks, significance was reached, and it was no longer significant at 32 weeks. Two studies examined the effect of soy consumption on hot flushes. One study found a significant decrease of ADT-associated vasomotor symptoms in the soy protein and placebo group \[[@CR18]\]. Sharma et al. observed no change.

Surprisingly, a significant difference in favor of the placebo group was found \[[@CR11]\].

#### Overweight {#Sec18}

ADT may cause metabolic effects including dyslipidemia, elevated fasting serum glucose, weight gain, and increase in fat mass. C-reactive protein (CRP) might be a marker of adverse metabolic effects. Seventeen studies reporting on exercise programs of varying duration, frequency, intensity, and degree of supervision showed conflicting results \[[@CR9], [@CR10], [@CR12]--[@CR14], [@CR16], [@CR17], [@CR20]--[@CR26], [@CR28]--[@CR32], [@CR36], [@CR37]\]. These articles mention aspects of body composition amounting to sixteen different items: weight, BMI, waist circumference, hip circumference, waist and neck girth, waist-to-hip ratio, mid-upper arm muscle area, total fat mass, percentage body fat, trunk fat mass, visceral fat mass, body lean mass, appendicular lean mass, and skeletal muscle mass. The effect of aerobic and/or resistance training on body composition was examined in thirteen studies. Three of these studies added dietary advice \[[@CR14], [@CR20], [@CR28]\].

Beneficial effects on one or multiple items reflecting body composition were found in eight of these studies (Table [2](#Tab2){ref-type="table"}).

O'neill et al. investigated the effect of aerobic training and dietary advice and showed an improvement in body composition \[[@CR26]\]. Two studies examined the effect of supervised football training \[[@CR21], [@CR32]\]. One study lasted 12 weeks, the other 32 weeks. Initially, a significant increase in lean body mass was reached after 12 weeks \[[@CR21]\]. At 32 weeks, this effect ceased to be significant. Endurance training showed an improvement of body composition \[[@CR16]\]. Metabolic syndrome is a clustering of at least three out of five following medical conditions: hypertension, hyperglycemia, abdominal obesity, high serum triglycerides, and a low high-density lipoproteins (HDL).

Blood biomarkers reflecting these changes were examined in six studies. A decrease in HDL/total cholesterol ratio was found by Cormie et al., who investigated the effects of a 12-week program combining aerobic and resistance training \[[@CR24]\]. An improvement in HDL was found over time after a program of endurance training \[[@CR16]\].

No other studies reported beneficial effects. The influence of aerobic and resistance training on CRP showed contradictory results. One study found a positive effect \[[@CR13]\], and two studies found no change \[[@CR24], [@CR36]\]. On microscopic level, the effect of resistance training in biopsies of the m. vastus lateralis was reported \[[@CR29], [@CR30]\]. An increase in total muscle fibers and type II fibers was shown \[[@CR29]\]. Muscle atrophy is associated with reduced mitochondrial function and increased muscle cellular stress, reflected by different heat shock proteins. Only HSP70 improved significantly \[[@CR30]\].

#### Cardiovascular health {#Sec19}

Factors influencing cardiovascular health are manifold: lipid profile, blood pressure, BMI, endothelial cell function, pro-inflammatory factors, and insulin resistance. ADT has a negative impact on these factors. Besides, there is an association between ADT and the occurrence of serious cardiac arrhythmias. Eleven studies investigated the effect of physical exercise of which three studies added dietary advice \[[@CR12], [@CR13], [@CR16]--[@CR18], [@CR24], [@CR26], [@CR28], [@CR36], [@CR37]\]. The results of these studies are contradictory. With respect to blood pressure, four studies found no effect on systolic or diastolic blood pressure between the groups \[[@CR12], [@CR20], [@CR24], [@CR28]\]. Culos-Reed et al. found a change in systolic and diastolic blood pressure over time in the aerobic and resistance training group \[[@CR12]\]. Using flow-mediated dilatation (FMD) as a measure, an improvement in the exercise combined with dietary advice group was found \[[@CR28]\]. The effect of training on maximum oxygen utilization (VO2 max) was investigated in five studies \[[@CR17], [@CR18], [@CR24], [@CR36], [@CR37]\]. Most of these studies consisted of a mixture of aerobic and/or resistance training. Uth et al. used football training. Almost consistently, an improvement was found.

Resistance training scored better in increasing cardiovascular fitness  than aerobic \[[@CR17], [@CR18]\]. Four studies found a significant improvement on cardiovascular fitness after physical exercises, measured by different tests \[[@CR13], [@CR26], [@CR29], [@CR35]\].

#### Insulin resistance {#Sec20}

It is not completely understood how ADT therapy deregulates glucose metabolism. Possibly hypogonadism, secondary to obesity, alters fatty acid metabolism or changes in skeletal muscle may play a role. The influence of exercise on insulin resistance was measured in seven studies \[[@CR13], [@CR14], [@CR16], [@CR22]--[@CR24], [@CR36], [@CR37]\]. One study added dietary advice. A glucose-lowering effect of exercise was shown in two studies \[[@CR16], [@CR36]\]. Wall et al. showed an improvement for glucose metabolism in combined aerobic and resistance training \[[@CR36]\]. Hvid et al. investigated the effect of endurance training on insulin resistance in men on ADT compared to healthy males and found a difference in fasting glucose over time in the per-group analysis \[[@CR16]\].

Using the oral glucose tolerance test (OGTT), no differences over time were found between the groups with regard to fasting glucose, fasting insulin, glucose AUC, and insulin AUC \[[@CR16]\]. Biomarkers: IGF-1, insulin, IFGBP-1 and IGFBP-3, and HBA1c failed to show a difference in any of the studies.

#### Osteoporosis {#Sec21}

Osteoporosis is a major concern in men undergoing ADT therapy, especially with prolonged use. Five studies investigated the effect of exercise modalities on osteoporosis \[[@CR24], [@CR25], [@CR32]--[@CR34]\]. We were unable to find any studies focusing on dietary advice. Dual x-ray absorptiometry (DEXA-scan) was used in all studies in order to examine bone mineral density (BMD) and bone mineral content (BMC). Blood biomarkers were examined in four studies. Biomarkers were alkaline phosphatase, P1NP, N-telopeptide, N-telopeptide/creatinine ratio, vitamin D, osteocalcin, CTX, NTX, and BS-ALP. Only Uth was able to show a significant improvement in different markers of osteoporosis. He found an increment in BMC after 12 weeks of supervised football training \[[@CR33]\]. Initially, BMD remained unchanged after 12 weeks of training \[[@CR33]\], whereas after 32 weeks, an increase in BMD was found in the total hip and femoral shaft \[[@CR32]\]. P1NP and osteocalcin were the only bone formation markers that showed a significant change. After 12 weeks, there was an increase in these markers \[[@CR32]\] After prolonged training (32 weeks), this increase no longer was significant \[[@CR32]\].

Discussion {#Sec22}
==========

This study focuses on lifestyle interventions to reduce the deleterious side effects of ADT. Twenty-nine RCTs reported the effect of different lifestyle interventions. The effect of exercises in different modalities and intensities was studied including measures such as dietary advice, self-education, CBT, or educational support program. We excluded therapies like prescribing calcium and vitamin D.

Regarding psychological effects, contradictory results were found. Many different questionnaires were used to examine the effect of lifestyle interventions on HRQOL, which make it hard to compare different outcomes and therefore it is difficult to make a straightforward conclusion about the effect of certain interventions.

Combining exercise with diet seems to have the most beneficial effects on HRQOL; all studies regarding this combination showed a significant improvement \[[@CR15], [@CR20], [@CR26]\]. Soy protein consumption was found in only one study to have a beneficial effect.

An earlier study found that ADT use conferred a 41% increased risk of depression \[[@CR38]\]. In this review, we were unable to find any difference in the occurrence of depression after applying lifestyle interventions, whereas in two studies an improvement of QOL was noted in absence of improvement of depression score \[[@CR24], [@CR37]\]. Tentative explanations for these outcomes can be the following. Both studies used different questionnaires to score quality of life and the occurrence of depression, making it difficult to compare them. In our review, we only noted the truly significant findings, but in the study of Cormie, where an improvement in various subscales of QOL was observed, a borderline significance was found in the depression score with a *P* value of 0054; this might be interpreted as a trend in improvement of physiological well-being \[[@CR24]\].

There were many different tools used to examine fatigue. Some used general questionnaires, and others applied prostate-specific tools (FACT-F) \[[@CR9], [@CR14], [@CR17], [@CR20], [@CR24]\]. Although there was a lack in using a common tool, different lifestyle interventions reduced fatigue and increased vitality. All studies used in this review examined physical exercises, sometimes combined with dietary advice. However, no attention was given to other lifestyle adjustments, such as smoking, alcohol use, or a balanced diet.

With regard to libido and sexual function, a possible beneficial effect of aerobic and resistance training was found \[[@CR15], [@CR24]\]. It is noteworthy that consuming soy protein did not have any effect \[[@CR11]\]. Considering the age group for which ADT therapy is applied, we can expect a general natural decline of libido and sexual function.

Gynecomastia may very well occur after weight gain. Only one author reported on this subject \[[@CR17]\]. This might reflect a disbelief in the effect of lifestyle changes on gynecomastia. A variety of medical therapies exist such as radiation therapy or lipolysis \[[@CR39]\].

Two strategies were examined to reduce vasomotor symptoms. Although soy proteins appears to be successful in treating hot flushes in postmenopausal women \[[@CR40]\], in men on ADT, they are unsuccessful. CBT appears to be helpful in managing hot flushes. Limitations of this study were the small sample size and short period of self-guided therapy. Further research might look into additional variables such as caffeine intake and other specific health problems.

In this study, we divided the metabolic changes into three subcategories: overweight, insulin resistance, and cardiovascular health. These categories are interrelated. Concerning insulin resistance, studies failed to show a difference between men with ADT undergoing physical exercises or not, when measured by fasting glucose. Endurance training, however, showed no differences in OGTT between men on ADT undergoing exercises versus healthy men \[[@CR16]\]. No trial used the novo diabetes mellitus as an outcome.

Overweight was examined in 17 studies. All studies investigated the effect of exercise, and four studies added nutritional advice. Evidence was found that solely exercise or exercise combined with nutritional advice may decrease overweight. The influence of a dietary advice only on obesity hasn't been investigated. Earlier studies showed the major impact of an appropriate diet in the prevention of obesity in the healthy old male population \[[@CR41]\].

Considering osteoporosis, one study suggests that regularly practicing football may mitigate ADT-induced decline in BMD. However, aerobic or resistance training failed to show this decline. Future studies should investigate the effects of different exercise modalities.

National osteoporosis foundation recommends a daily calcium intake of 1200 mg and supplemental vitamin D of 800--1000 IU to maintain bone health \[[@CR42]\]. In this review, there was not one study, which focused on an adequate intake as described above. As mentioned earlier, we did not include RCTs in which calcium and Vitamin D were prescribed. A systematic review conducted in 2012, which investigated the effect of calcium and vitamin D suppletion in men with PCa using ADT showed conflicting effects \[[@CR43]\]. It would be interesting to conduct studies in which dietary advice is given to promote sufficient intake of calcium and vitamin D and investigate this effect on the development of osteoporosis in patients on ADT.

A number of limitations in this review must be considered. Firstly, we focused on two databases, PubMed and Medline, since these two are the most widely used and recognized. Secondly, there was substantial heterogeneity in life style interventions, in which some interventions were investigated frequently, while other interventions only once. This makes it impossible to compare the effects of different strategies and draw conclusions about the efficacy of these interventions. Additionally, we did not investigate the effect of duration of exercise, dietary advice, or other behavioral components.

There was a variety in quality of the different RCTs. Especially, the prevention of performance bias was often inadequate, due to the fact it was impossible to blind participants following lifestyle programs. Despite these limitations, evidence suggests that lifestyle interventions may have a beneficial effect on ADT-mediated side effects.

Conclusions {#Sec23}
===========

Adverse effects of ADT are manifold as well as the various lifestyle interventions aimed to alleviate these side effects. Physical exercises demonstrated to have a mainly positive effect on cardiovascular health. Contradictory results were found regarding quality of life, libido, fatigue, insulin resistance, overweight, and osteoporosis. No effect was found regarding depression and gynecomastia. Regarding dietary advice, soy protein showed no beneficial effect on libido or fatigue. No other studies allowed conclusions on dietary advice solely. A positive effect was shown with CBT on the occurrence of hot flushes. Other behavioral components failed to show a significant effect regarding side effects. Further research is necessary to identify the most effective interventions for the individual patient.
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